Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden–High Ovarian Cancer

20260 citationsJournal Articlehybrid Open Access

Authors

Robert L. Coleman · Shenandoah Oncology

Rodney P. Rocconi · University of Mississippi Medical Center

Bradley J. Monk · Florida Cancer Specialists & Research Institute

Adam Walter · Gradalis (United States)

Laura Stanbery · Gradalis (United States)

David Willoughby · Historic Deerfield

Casey Nagel

Abstract

These results demonstrate OS advantage for maintenance treatment of adult females with newly diagnosed, advanced stage IIIb-IV ovarian cancer with HRP status and cTMB-H profile who are in complete response after debulking surgery and frontline platinum-based doublet chemotherapy.

Topics & Keywords

PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment Protein Degradation and Inhibitors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JCO Precision Oncology

Volume 10, Issue 1, pp. e2500462-e2500462

DOI: 10.1200/po-25-00462

Field-Weighted Citation Impact: 0.00